Research Program in Intermediate Energy Physics

中间能源物理研究项目

基本信息

  • 批准号:
    0402151
  • 负责人:
  • 金额:
    $ 8.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Continuing Grant
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-08-15 至 2006-07-31
  • 项目状态:
    已结题

项目摘要

Experiments in meson spectroscopy test critical aspects of the standardtheory of the strong nuclear force. Although they only live for a shorttime before they decay, mesons provide a unique laboratory for the studyof the strong force because they are the simplest quark configuration,just a one quark and one antiquark. The GlueX experiment is a major newinitiative being undertaken at Jefferson Lab in Newport News, Virginiausing polarized photons from the CEBAF electron accelerator to searchfor a new class of excitations known as exotic mesons. Although exoticswere predicted based upon the standard theory over 20 years ago,conclusive experimental evidence for their existence has not yet beenestablished. The P.I. is a member of the governing board of the GlueXexperiment and has specific responsibility in the design andconstruction of the polarized photon source. A preliminary step towardsthe larger goals of GlueX was the Radphi experiment was constructedstudy the decays of a known meson, the phi(1020). The phi itself is notexotic, but some evidence pointed to the possible exotic nature of twoother mesons at around the same mass, the a0(980) and the f0(980). Radiative decays of the phi to these scalars provide an important testof this hypothesis. The experiment collected its data during a 60-dayrun in summer 2000, and is in the final stages of data analysis. TheP.I. is also involved in the Qweak experiment at Jefferson Lab, whichundertakes a precise measurement of the weak charge of the proton as asearch for physics beyond the Standard Model. In this project he hasshared responsibility for the Compton-backscatter electron polarimeter.
介子光谱实验检验了强核力标准理论的关键方面。虽然介子在衰变前只存在很短的时间,但它们为研究强作用力提供了一个独特的实验室,因为它们是最简单的夸克构型,只有一个夸克和一个反夸克。GlueX实验是弗吉尼亚州纽波特纽斯的杰斐逊实验室进行的一项重大创新,它利用CEBAF电子加速器的偏振光子来寻找一种被称为外来介子的新激发。虽然20多年前就根据标准理论预测了外来物种,但它们存在的确凿实验证据尚未建立。P.I.是GlueXexperiment管理委员会的成员,在偏振光子源的设计和构建中负有特定的责任。为了实现GlueX更大的目标,Radphi实验是为了研究已知介子的衰变而建立的。π本身并不是奇异的,但是一些证据指出了具有相同质量的另外两个介子——a0(980)和f0(980)——可能具有奇异的性质。对这些标量的辐射衰减为这个假设提供了一个重要的检验。该实验于2000年夏季进行了60天的实验,收集了数据,目前已进入数据分析的最后阶段。TheP.I。他还参与了杰斐逊实验室的Qweak实验,该实验负责对质子的弱电荷进行精确测量,以寻找超越标准模型的物理。在这个项目中,他共同负责康普顿后向散射电子偏振计。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Jones其他文献

A fresh look at continuous subcutaneous insulin infusion
持续皮下胰岛素输注的新视角
Peri-operative care considerations for primary total knee arthroplasty in the obese patient
肥胖患者初次全膝关节置换术的围手术期护理注意事项
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    J. Romero;Richard Jones;T. Brown
  • 通讯作者:
    T. Brown
Assessment of surgeon variability in preoperative planning of reverse total shoulder arthroplasty: a quantitative comparison of 49 cases planned by 9 surgeons.
反向全肩关节置换术术前计划的外科医生变异性评估:对 9 名外科医生计划的 49 例病例的定量比较。
  • DOI:
    10.1016/j.jse.2020.02.023
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Moby Parsons;A. Greene;S. Polakovic;I. Byram;E. Cheung;Richard Jones;R. Papandrea;A. Youderian;T. Wright;P. Flurin;J. Zuckerman
  • 通讯作者:
    J. Zuckerman
Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.
评估促炎细胞因子和炎症标志物作为噻唑烷二酮类药物在 2 型糖尿病患者和健康志愿者中作用的生物标志物。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Martijn B. A. van Doorn;M. Kemme;M. Ouwens;E. V. van Hoogdalem;Richard Jones;H. Romijn;M. D. de Kam;R. Schoemaker;K. Burggraaf;A. Cohen
  • 通讯作者:
    A. Cohen
Why Remittances Shouldn’t Be Blamed for Rural Underdevelopment in Mexico
为什么墨西哥农村不发达不应归咎于汇款
  • DOI:
    10.1177/0308275x05048614
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    Jeffrey H. Cohen;Richard Jones;D. Conway
  • 通讯作者:
    D. Conway

Richard Jones的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Jones', 18)}}的其他基金

Research and Education with GlueX
使用 GlueX 进行研究和教育
  • 批准号:
    2209480
  • 财政年份:
    2022
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Continuing Grant
Enhancing UK Flood Resilience: Past Floods, Present Threats, Future Responses
增强英国的防洪能力:过去的洪水、当前的威胁、未来的应对措施
  • 批准号:
    AH/T006064/1
  • 财政年份:
    2020
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Research Grant
CC* Compute: Shared Computing Infrastructure for Large-scale Science Problems
CC* 计算:解决大规模科学问题的共享计算基础设施
  • 批准号:
    1925716
  • 财政年份:
    2019
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Standard Grant
Research and Education with GlueX
使用 GlueX 进行研究和教育
  • 批准号:
    1812415
  • 财政年份:
    2018
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Continuing Grant
Unweaving the Rainbow: exploring colour with art and synchrotron radiation
解开彩虹:用艺术和同步辐射探索色彩
  • 批准号:
    ST/R001731/1
  • 财政年份:
    2017
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Research Grant
Rational design of manufacturing processes for next generation optoelectronically active nanocomposite films and coatings
合理设计下一代光电活性纳米复合薄膜和涂层的制造工艺
  • 批准号:
    EP/P027814/1
  • 财政年份:
    2017
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Research Grant
Supporting post-doc and professional staff exchanges with external partners includingindustry on projects in the healthcare area
支持博士后和专业人员与外部合作伙伴(包括医疗保健领域项目的行业)的交流
  • 批准号:
    MC_PC_15062
  • 财政年份:
    2016
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Intramural
Future Resilience for African CiTies And Lands (FRACTAL)
非洲城市和土地的未来复原力(分形)
  • 批准号:
    NE/M020061/1
  • 财政年份:
    2015
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Research Grant
Experimental Equipment Call
实验设备调用
  • 批准号:
    EP/M028437/1
  • 财政年份:
    2015
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Research Grant
Research and Education with GlueX
使用 GlueX 进行研究和教育
  • 批准号:
    1508238
  • 财政年份:
    2015
  • 资助金额:
    $ 8.53万
  • 项目类别:
    Continuing Grant

相似海外基金

Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
基本标题:预防临床前药物开发计划:临床前功效和中间终点生物标志物任务顺序标题:TPST-1495 在 PIRC 大鼠模型中预防结直肠癌 (CRC)
  • 批准号:
    10927554
  • 财政年份:
    2023
  • 资助金额:
    $ 8.53万
  • 项目类别:
PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate BiomarkersTask Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma
PREVENT 临床前药物开发计划:临床前功效和中间生物标志物任务单标题:萝卜硫素用于预防恶性间皮瘤
  • 批准号:
    10836806
  • 财政年份:
    2023
  • 资助金额:
    $ 8.53万
  • 项目类别:
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
基本标题:预防临床前药物开发计划:临床前疗效和中间终点 BIOMAKERSTASK 订单标题:再次疫苗
  • 批准号:
    10651935
  • 财政年份:
    2022
  • 资助金额:
    $ 8.53万
  • 项目类别:
PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers-- Targeting the PARP Pathway for the Prevention of Breast Cancer
PREVENT Cancer临床前药物开发计划:临床前疗效和中间终点生物标志物——靶向PARP通路预防乳腺癌
  • 批准号:
    10629488
  • 财政年份:
    2022
  • 资助金额:
    $ 8.53万
  • 项目类别:
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
基本标题:预防临床前药物开发计划:临床前疗效和中间生物标志物订单标题:预防 FAP-CRC 使用
  • 批准号:
    10652736
  • 财政年份:
    2022
  • 资助金额:
    $ 8.53万
  • 项目类别:
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
预防临床前药物开发计划:临床前疗效和中间生物标志物;
  • 批准号:
    10412368
  • 财政年份:
    2021
  • 资助金额:
    $ 8.53万
  • 项目类别:
BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR
基础:预防临床前药物开发计划:临床前疗效
  • 批准号:
    10201174
  • 财政年份:
    2020
  • 资助金额:
    $ 8.53万
  • 项目类别:
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
预防计划:临床前疗效和中间终点生物标志物;
  • 批准号:
    10269186
  • 财政年份:
    2020
  • 资助金额:
    $ 8.53万
  • 项目类别:
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
预防计划:临床前疗效和中间终点生物标志物;
  • 批准号:
    10598444
  • 财政年份:
    2020
  • 资助金额:
    $ 8.53万
  • 项目类别:
IGF::OT::IGF PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS.TASK ORDER: CONTRACT ORIENTATION AND KICK-OFF MEETING. POP 09/22/2015 - 12/31/2015
IGF::OT::IGF 临床前预防癌症计划:临床前疗效和中间终点生物标志物。任务顺序:合同说明会和启动会议。
  • 批准号:
    9150964
  • 财政年份:
    2015
  • 资助金额:
    $ 8.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了